-+ 0.00%
-+ 0.00%
-+ 0.00%
The Zhitong Finance App learned that on November 19, Genting Xinyao (01952.HK) announced that the VIS-101 phase IIb Ascend clinical study to treat wet age-related macular degeneration (wet AMD) had completed the first patient administration.
Share
Listen to the news
The Zhitong Finance App learned that on November 19, Genting Xinyao (01952.HK) announced that the VIS-101 phase IIb Ascend clinical study to treat wet age-related macular degeneration (wet AMD) had completed the first patient administration.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending